Fibrotest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C [3]

Hepatology

Volumn 47, Issue 1, 2008, Pages 353-354

  Morra, Rachel ^a   Lebray, Pascal ^a   Ingiliz, Patrick ^a   Ngo, Yen ^a   Munteanu, Mona ^b   Ratziu, Vlad ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Biopredictive   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

CONFIDENCE INTERVAL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ELASTOGRAPHY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEPATITIS C; HUMAN; LETTER; LIVER BIOPSY; LIVER FIBROSIS; PRIORITY JOURNAL; PROGNOSIS; STANDARDIZATION; THROMBOCYTE;

ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; PLATELET COUNT; PROGNOSIS;

EID: 38649103786     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22046     Document Type: Letter

References (15)

1. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. HEPATOLOGY 2007;46:912-921.
2. Ferard G, Imbert-Bismut F, Messous D, Piton A, Ueda S, Poynard T, et al. A reference material for traceability of aspartate aminotransferase (AST) results. Clin Chem Lab Med 2005;43:549-553.
3. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al., and the MULTIVIRC Group. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. HEPATOLOGY 1998;27:1213-1219.
4. Ferard G, Piton A, Messous D, Imbert-Bismut F, Frairi A, Poynard T, et al. Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to Fibrotest and Actitest scores. Clin Chem Lab Med 2006;44:400-406.
5. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al., and the FibroPaca Group. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007;53:1615-1622.
6. La Haute Autorité de Santé (HAS) in France. The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers. Available at: http://www.has-sante.ft/portail/display.jsp?id= c_476486. Accessed August 2007.
7. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, et al. Fibrotest has higher predictive values than APRI for fibrosis diagnosis in patients with chronic hepatitis C [Letter]. HEPATOLOGY 2004; 39:862-863.
8. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
9. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. HEPATOLOGY 2005;42:1373-1381.
10. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006;44:686-693.
11. Sène D, Limal N, Messous D, Ghillani-Dalbin P, Charlotte F, Halfon P, et al. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis. Clin Biochem 2006;39:715-721.
12. Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007;46:775-782.
13. Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007;46:395-402.
14. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52: 1887-1896.
15. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003, 38;1449-1457.